Studio di ARTS-021 in pazienti con tumori solidi avanzati
Uno studio di fase 1/2, primo sull'uomo per valutare la sicurezza, la tollerabilità, la farmacocinetica, la farmacodinamica, l'MTD/RP2D e l'attività antitumorale di ARTS-021 come agente singolo e in terapia di combinazione in pazienti con tumori solidi
This study, the first clinical trial of AVZO-021, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-021 in patients with advanced solid tumors. AVZO-021 is an oral medication that inhibits cyclin-dependent kinase 2 (CDK 2).
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
AVZO-021 is a compound being developed for the treatment of patients with advanced solid tumors, specifically, HR+/HER2- breast cancer and cyclin E1 (CCNE1) altered malignancies. AVZO-021 is a selective and potent cyclin-dependent kinase 2 (CDK2) inhibitor, which plays an important role in cell cycle regulation. This is a Phase 1/2 first-in-human, open-label, nonrandomized, multicenter study of AVZO-021. Phase 1 is a dose-escalation phase aimed at assessing the safety and tolerability of AVZO-021 and determining the recommended phase 2 dose (RP2D) as monotherapy and combination therapy. Phase 2 is a dose-expansion phase that will be conducted to assess the antitumor activity of AVZO-021 as monotherapy and combination therapy.
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 2
- Fase 1
Contatti e Sedi
Contatto studio
- Nome: Medical Information
- Numero di telefono: (858) 239-2944
- Email: ClinicalTrials@avenzotx.com
Luoghi di studio
-
-
New South Wales
-
Macquarie University, New South Wales, Australia
- Reclutamento
- Avenzo Therapeutics Recruiting Site
-
Contatto:
- Avenzo Therapeutics
-
Wollongong, New South Wales, Australia
- Reclutamento
- Avenzo Therapeutics Recruiting Site
-
Contatto:
- Avenzo Therapeutics
-
-
-
-
Connecticut
-
New Haven, Connecticut, Stati Uniti, 06520
- Reclutamento
- Avenzo Therapeutics Recruiting Site
-
Contatto:
- Avenzo Therapeutics
-
-
Florida
-
Sarasota, Florida, Stati Uniti, 34232
- Reclutamento
- Avenzo Therapeutics Recruiting Site
-
Contatto:
- Avenzo Therapeutics
-
Tampa, Florida, Stati Uniti, 33612
- Reclutamento
- Avenzo Therapeutics Recruiting Site
-
Contatto:
- Avenzo Therapeutics
-
-
New York
-
Mineola, New York, Stati Uniti, 11501
- Reclutamento
- Avenzo Therapeutics Recruiting Site
-
Contatto:
- Avenzo Therapeutics
-
New York, New York, Stati Uniti, 10016
- Reclutamento
- Avenzo Therapeutics Recruiting Site
-
Contatto:
- Avenzo Therapeutics
-
-
Ohio
-
Cleveland, Ohio, Stati Uniti, 44106
- Reclutamento
- Avenzo Therapeutics Recruiting Site
-
Contatto:
- Avenzo Therapeutics
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Stati Uniti, 73117
- Reclutamento
- Avenzo Therapeutics Recruiting Site
-
Contatto:
- Avenzo Therapeutics
-
-
Oregon
-
Portland, Oregon, Stati Uniti, 97213
- Reclutamento
- Avenzo Therapeutics Recruiting Site
-
Contatto:
- Avenzo Therapeutics
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Stati Uniti, 19107
- Reclutamento
- Avenzo Therapeutics Recruiting Site
-
Contatto:
- Avenzo Therapeutics
-
-
Texas
-
Dallas, Texas, Stati Uniti, 75246
- Reclutamento
- Avenzo Therapeutics Recruiting Site
-
Contatto:
- Avenzo Therapeutics
-
-
Virginia
-
Fairfax, Virginia, Stati Uniti, 22031
- Reclutamento
- Avenzo Therapeutics Recruiting Site
-
Contatto:
- Avenzo Therapeutics
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Key Inclusion Criteria:
-
Male or female aged ≥18 years old at screening with Eastern Cooperative Oncology Group (ECOG) 0-1.
-
Disease-related inclusion criteria by study phase and part:
i) Phase 1a Monotherapy Dose Escalation: Patients with locally advanced or metastatic HR+/HER2- breast cancer, CCNE1-amplified tumors that are either epithelial ovarian cancer, primary peritoneal cancer, fallopian tube cancer, endometrial cancer or TNBC, with no other oncogenic driver mutations that are treatable and standard therapies are no longer effective, appropriate, or safe in the opinion of the investigator and medical monitor. Patients with any additional tumor type with CCNE1 amplification can be enrolled only if clinical data is supportive and approved by medical monitor (Cohort 1A).
ii) Phase 1b Combination Dose Escalation: histologically or cytologically confirmed diagnosis of locally advanced or metastatic HR+ HER2- (HER2-low may be allowed if failed standard of care therapy) breast cancer, who have been previously treated with inhibitor of CDK4/6 and endocrine therapy(Cohorts 1B1, 1B2, 1B3, 1B4, and 1B5); or histologically or cytologically confirmed diagnosis of CCNE1- amplified, locally advanced or metastatic, platinum-refractory or platinum-resistant EOC, primary peritoneal, or fallopian tube cancer (Cohort 1C).
iii) Phase 2a Monotherapy dose expansion: Histologically or cytologically confirmed diagnosis of locally advanced or metastatic CCNE1 amplified epithelial ovarian cancer, primary peritoneal cancer, fallopian tube cancer, endometrial cancer or TNBC, with no other oncogenic driver mutations that are treatable and standard therapies are no longer effective, appropriate, or safe in the opinion of the investigator and medical monitor (Cohort 2A).
iv) Phase 2b Combination dose expansion: Histologically or cytologically confirmed diagnosis of locally advanced or metastatic HR+/HER2- (HER2-low may be allowed if failed standard of care therapy) breast cancer who have been previously treated with no more than 1 prior CDK4/6 inhibitor and endocrine therapy (Cohorts 2B1, 2B2, 2B3, 2B4, and 2B5); or Histologically or cytologically confirmed diagnosis of locally advanced or metastatic, CCNE1-amplified, platinum-refractory or platinum-resistant EOC, primary peritoneal cancer, or fallopian tube cancer (Cohort 2C).
-
No more than 2 prior cytotoxic chemotherapy regimens for locally advanced/metastatic disease (excepting patients treated with an antibody-drug conjugate, with ovarian cancer if there disease is platinum resistant or refractory, having progressed beyond all SOC care; and patients who have received prior chemotherapy in the adjuvant or neoadjuvant setting >12 months prior to starting AVZO-021 treatment).
-
Measurable disease as determined by RECIST version 1.1.
-
Adequate bone marrow and organ function.
-
Ability to swallow capsules or tablets.
Key Exclusion Criteria:
- Received an investigational agent or anticancer therapy within 2 weeks, or 5 half-lives of the drug, whichever is shorter, prior to planned start of AVZO-021.
- Received any CDK2 inhibitor, protein kinase membrane associated tyrosine/threonine 1 (PKMYT1) inhibitor, or WEE1 inhibitor anticancer therapy. For cohort B5, prior therapy with topoisomerase inhibitors is not permitted.
- Undergone major surgery within 4 weeks prior to planned start of AVZO-021.
- Received radiotherapy for palliation within 7 days of the first dose of study treatment, unless specified otherwise in the protocol.
- Active CNS metastases or confirmed leptomeningeal disease are not eligible.
- Unresolved toxicities from prior therapy greater than Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 Grade >1 at the time of starting study treatment.
- Clinically unstable cardiac function as described in the protocol.
- Any active or chronic infection/disease that compromises the immune system.
- Current treatment with strong or moderate cytochrome P450 (CYP)3A4 inhibitors or inducers.
- Active second malignancy unless in remission with life expectancy > 2 years and with documented sponsor approval.
- Pregnancy, lactation, or plans to breastfeed during the study or within 6 months of the last dose of study intervention.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione sequenziale
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Phase 1, monotherapy (Part 1A)
Escalating doses of once daily, oral AVZO-021 in 28-day cycles. |
AVZO-021 is a selective and potent oral inhibitor of CDK2 being developed for the treatment of patients with advanced solid tumors with CDK2 dependency (1A), CCNE1 amplified solid tumors (2A), HR+/HER2- BC (1B1-1B5, 2B1-2B5) and CCNE1 amplified EOC (1C, 2C) |
|
Sperimentale: Phase 1, combination (Parts 1B and 1C)
Escalating doses of once daily, oral AVZO-021 in 28-day cycles starting at least 1 DL below the monotherapy MTD/RP2D dose in combination with: 1B1) fulvestrant 1B2) palbociclib plus either fulvestrant or letrozole 1B3) ribociclib plus either fulvestrant or letrozole 1B4) abemaciclib plus either fulvestrant or letrozole 1B5) sacituzumab govitecan-hziy 1C) carboplatin |
AVZO-021 is a selective and potent oral inhibitor of CDK2 being developed for the treatment of patients with advanced solid tumors with CDK2 dependency (1A), CCNE1 amplified solid tumors (2A), HR+/HER2- BC (1B1-1B5, 2B1-2B5) and CCNE1 amplified EOC (1C, 2C) Antineoplastic agent, cyclin-dependent kinase 4/6 inhibitor
Altri nomi:
Antineoplastic agent, estrogen receptor antagonist
Altri nomi:
Antineoplastic agent, aromatase inhibitor
Altri nomi:
Antineoplastic CDK4/6 inhibitor
Altri nomi:
Antineoplastic CDK4/6 inhibitor
Altri nomi:
Alkylating agent Trop-2 antibody and topoisomerase inhibitor
Altri nomi:
|
|
Sperimentale: Phase 2, monotherapy (Part 2A)
Oral doses of AVZO-021 in 28-day cycles at the RP2D determined in Part 1A. |
AVZO-021 is a selective and potent oral inhibitor of CDK2 being developed for the treatment of patients with advanced solid tumors with CDK2 dependency (1A), CCNE1 amplified solid tumors (2A), HR+/HER2- BC (1B1-1B5, 2B1-2B5) and CCNE1 amplified EOC (1C, 2C) |
|
Sperimentale: Phase 2, combination (Parts 2B and 2C)
Oral doses of AVZO-021 in 28-day cycles at the RP2D determined in Parts 1B/1C, in combination with: 2B1) fulvestrant 2B2) palbociclib plus either fulvestrant or letrozole 2B3) ribociclib plus either fulvestrant or letrozole 2B4) abemaciclib plus either fulvestrant or letrozole 2B5) sacituzumab govitecan-hziy 2C) carboplatin |
AVZO-021 is a selective and potent oral inhibitor of CDK2 being developed for the treatment of patients with advanced solid tumors with CDK2 dependency (1A), CCNE1 amplified solid tumors (2A), HR+/HER2- BC (1B1-1B5, 2B1-2B5) and CCNE1 amplified EOC (1C, 2C) Antineoplastic agent, cyclin-dependent kinase 4/6 inhibitor
Altri nomi:
Antineoplastic agent, estrogen receptor antagonist
Altri nomi:
Antineoplastic agent, aromatase inhibitor
Altri nomi:
Antineoplastic CDK4/6 inhibitor
Altri nomi:
Antineoplastic CDK4/6 inhibitor
Altri nomi:
Alkylating agent Trop-2 antibody and topoisomerase inhibitor
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Occurrence of Dose Limiting Toxicities (DLTs) during the first cycle (Phase 1)
Lasso di tempo: 28 Days
|
Number of participants with DLTs assessed for severity using CTCAE v5.0 criteria will be summarized by dose level. |
28 Days
|
|
Number of Participants with Treatment Emergent Adverse Events (TEAEs) and lab abnormalities (Phase 1)
Lasso di tempo: Approximately 22 months
|
To evaluate the type, incidence, severity, timing, seriousness, and relationship to study treatment of adverse events and any laboratory abnormalities summarized by dose level. |
Approximately 22 months
|
|
Determination of Recommended Phase 2 Dose (RP2D) (Phase 1)
Lasso di tempo: Approximately 16 months
|
RP2D for AVZO-021 is less than or the same as the maximum tolerated dose (MTD) as defined by the occurrence of DLTs and TEAEs calculated using isotonic regression. |
Approximately 16 months
|
|
Objective Response Rate (ORR) (Phase 2)
Lasso di tempo: Approximately 52 months
|
Defined as the proportion of patients with a confirmed Complete Response (CR) or Partial Response (PR), as determined by the investigator by radiographic disease assessment according to RECIST v1.1. |
Approximately 52 months
|
|
Progression Free Survival (PFS) (Phase 2)
Lasso di tempo: Approximately 52 months
|
Defined as the time from study drug treatment to death or disease progression, as determined by the investigator by radiographic disease assessment according to RECIST v1.1. |
Approximately 52 months
|
|
Overall Survival (OS) (Phase 2)
Lasso di tempo: Approximately 76 months
|
Defined as the time from study drug treatment initiation to death from any cause. |
Approximately 76 months
|
|
Duration of response (DOR) (Phase 2)
Lasso di tempo: Approximately 52 months
|
Defined as the time from the first confirmed response to radiologic/objective progression. |
Approximately 52 months
|
Misure di risultato secondarie
Misura del risultato |
Lasso di tempo |
|---|---|
|
Parametri farmacocinetici: concentrazione plasmatica massima (Cmax) (monoterapia e combinazione)
Lasso di tempo: Ciclo 1 giorni 1, 2, 8, 14 e 15 (ogni ciclo dura 28 giorni)
|
Ciclo 1 giorni 1, 2, 8, 14 e 15 (ogni ciclo dura 28 giorni)
|
|
Parametri farmacocinetici: tempo alla concentrazione plasmatica massima (Tmax) (monoterapia e combinazione)
Lasso di tempo: Ciclo 1 giorni 1, 2, 8, 14 e 15 (ogni ciclo dura 28 giorni)
|
Ciclo 1 giorni 1, 2, 8, 14 e 15 (ogni ciclo dura 28 giorni)
|
|
Parametri farmacocinetici: area sotto la curva concentrazione plasmatica-tempo dal tempo 0 all'ultima concentrazione misurabile (AUC 0-ultima) (monoterapia e combinazione)
Lasso di tempo: Ciclo 1 giorni 1, 2, 8, 14 e 15 (ogni ciclo dura 28 giorni)
|
Ciclo 1 giorni 1, 2, 8, 14 e 15 (ogni ciclo dura 28 giorni)
|
|
Parametri farmacocinetici: area sotto la curva concentrazione plasmatica-tempo dal tempo 0 all'ultima concentrazione misurabile (AUC 0-tau) (monoterapia e combinazione)
Lasso di tempo: Ciclo 1 giorni 1, 2, 8, 14 e 15 (ogni ciclo dura 28 giorni)
|
Ciclo 1 giorni 1, 2, 8, 14 e 15 (ogni ciclo dura 28 giorni)
|
|
Parametri farmacocinetici: concentrazione plasmatica minima osservata allo stato stazionario (Cmin, ss) (monoterapia e combinazione)
Lasso di tempo: Ciclo 1 giorni 1, 2, 8, 14 e 15 (ogni ciclo dura 28 giorni)
|
Ciclo 1 giorni 1, 2, 8, 14 e 15 (ogni ciclo dura 28 giorni)
|
|
Parametri farmacocinetici: razione di accumulo (Rac) (monoterapia e combinazione)
Lasso di tempo: Ciclo 1 giorni 1, 2, 8, 14 e 15 (ogni ciclo dura 28 giorni)
|
Ciclo 1 giorni 1, 2, 8, 14 e 15 (ogni ciclo dura 28 giorni)
|
|
Parametri farmacocinetici: emivita di eliminazione (t1/2) (monoterapia e combinazione)
Lasso di tempo: Ciclo 1 giorni 1, 2, 8, 14 e 15 (ogni ciclo dura 28 giorni)
|
Ciclo 1 giorni 1, 2, 8, 14 e 15 (ogni ciclo dura 28 giorni)
|
|
Parametri farmacocinetici: Clearance apparente (CL/F) (monoterapia e combinazione)
Lasso di tempo: Ciclo 1 giorni 1, 2, 8, 14 e 15 (ogni ciclo dura 28 giorni)
|
Ciclo 1 giorni 1, 2, 8, 14 e 15 (ogni ciclo dura 28 giorni)
|
|
Parametri PK: volume di distribuzione apparente durante la fase terminale (Vz/F) (monoterapia e combinazione)
Lasso di tempo: Ciclo 1 giorni 1, 2, 8, 14 e 15 (ogni ciclo dura 28 giorni)
|
Ciclo 1 giorni 1, 2, 8, 14 e 15 (ogni ciclo dura 28 giorni)
|
|
Valutare l'effetto di un pasto ricco di grassi sulla farmacocinetica di AVZO-021 (Fase 1)
Lasso di tempo: 5 giorni
|
5 giorni
|
Collaboratori e investigatori
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Malattie urogenitali
- Malattie genitali
- Malattie del sistema endocrino
- Neoplasie urogenitali
- Neoplasie per sede
- Neoplasie
- Malattie urogenitali femminili
- Malattie urogenitali femminili e complicanze della gravidanza
- Neoplasie per tipo istologico
- Malattie uterine
- Malattie genitali, femmina
- Neoplasie delle ghiandole endocrine
- Neoplasie, ghiandolari ed epiteliali
- Malattie ovariche
- Malattie annessiali
- Neoplasie genitali, femmina
- Disturbi gonadici
- Malattie della pelle
- Malattie del seno
- Carcinoma
- Neoplasie uterine
- Malattie delle tube di Falloppio
- Neoplasie ovariche
- Malattie della pelle e del tessuto connettivo
- Carcinoma, epiteliale ovarico
- Neoplasie mammarie
- Neoplasie mammarie triplo negativo
- Neoplasie endometriali
- Neoplasie delle tube di Falloppio
- Ormoni
- Ormoni, sostituti ormonali e antagonisti ormonali
- Prodotti chimici organici
- Composti eterociclici, 1-anello
- Composti eterociclici
- Azoli
- Composti policiclici
- Complessi di coordinamento
- Steroidi
- Composti anelli fusi
- Nitrili
- Estradiolo
- Estrene
- Estrane
- Congeneri di estradiolo
- Ormoni steroidi gonadali
- Ormoni gonadali
- Triazoli
- Letrozolo
- Fulvestrant
- Carboplatino
- Abemaciclib
- ribociclib
- Palbociclib
- GOVITECAN SACITUZUMAB
Altri numeri di identificazione dello studio
- AVZO-021-1001
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .